PIPGEN - PhD Project 1: Mechanism of action of PIK3CA mutation in cancer and overgrowth.
Research · University College of London (UCL)>UK
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 27 June 2021
EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
PhD Project details
Activating PIK3CA mutations lead to cancer and the PIK3CA-related overgrowth spectrum (PROS). Despite years of investigation, many questions remain about PIK3CA biology, signalling and pathway regulation. The aim of this project is to understand context-dependent and PIK3CA-mutant-specific biology, and how to therapeutically interfere with this pathway, both in cancer and PROS. We have made several interesting novel observations on PIK3CA biology and signalling that will be explored in this project, using advanced genetic and pharmacological PI3K approaches. Drug interventions will be tested in in vitro and in vivo studies.
Host: University College of London , UK.
Supervisor: Prof Bart Vanhaesebroeck.
Doctoral programme: University College of London.
Envisioned secondments: Josep Carreras Institute , qGenomics.
To apply for the UCL positions, in addition to the procedures outlined here, a further application will need to be completed via the UCL website – this is to conform with UCL’s own recruitment process. This second step is not yet available online, but we will inform candidates as soon as it opens.